Novel therapies for open-angle glaucoma

Scott M. Wentz, Nathaniel J. Kim, Jenny Wang, Annahita Amireskandari, Brent Siesky, Alon Harris

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.

Original languageEnglish (US)
Article number102
JournalF1000Prime Reports
Volume6
DOIs
StatePublished - Nov 4 2014

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Novel therapies for open-angle glaucoma. / Wentz, Scott M.; Kim, Nathaniel J.; Wang, Jenny; Amireskandari, Annahita; Siesky, Brent; Harris, Alon.

In: F1000Prime Reports, Vol. 6, 102, 04.11.2014.

Research output: Contribution to journalArticle